Skip to content
Research Article Open access CC BY 3.0

Economic Burden of Drug Therapy in Hypertension Management in a Private Teaching Hospital in Nigeria

Kehinde A. Ganiyu, Ismail A. Suleiman

Journal of Pharmaceutical Research International · pp. 70–78 · Published 5 Oct 2013

10.9734/BJPR/2014/3983

Abstract

Background: Information on economic burden of hypertension is needed for relevant decisions and policies due to escalating cost of disease management. Aims: The study assessed economic burden of pharmacotherapy in hypertension management on the National Health Insurance Scheme (NHIS) of Nigeria and the economies of antihypertensives selection. Study Design: Cross-sectional study. Place and Duration of Study: Out-patient-department of a private teaching hospital located in Lagos, Nigeria over four-month duration in 2011. Methodology: Two hundred and fifty case notes of hypertensive patients were randomly selected. These were assessed for costs of pharmacotherapeutic management of hypertension. Patients’ details such as demographic data, drug regimens and funding status were extracted from the case notes. Drugs’ prices were obtained from the hospital billing guide. Data presentation was by using descriptive statistics. Results: Two hundred and eight (83.2%) of the selected case notes met the study criteria. Diuretics were the most economical at an average monthly cost per prescription of NGN858.6 ($5.51) followed by the beta-blockers at NGN1,101.1 ($7.07) while fixed dose combinations were the costliest at NGN10,425.0 ($66.93). Health Maintenance Organizations (HMOs) having 104 (50.0%) of the cohort as enrollees incurred most of the cost at NGN446, 325.0 ($2,865.47) followed by NHIS 75 (36.0%) at NGN321, 354.0 ($2,063.14). An average monthly cost of antihypertensives per patient was highest for private patients NGN4, 314.47 ($27.69) and least for NHIS NGN4, 284.72 ($27.50). The national cost implication using the least average monthly antihypertensive cost per patient of NGN4,284 .72 ($27.50) for NHIS implies an average of NGN51,416.64 ($330.10) per annum for each patient and a whooping sum in excess of NGN1.054 trillion (over $6.76billion) for over 20 million affected hypertensive patients in Nigeria. Conclusion: Cost burden of hypertension management is high, incurred mostly by HMOs and NHIS. Diuretics were the most economical of all prescribed regimens.

Pharmacotherapeutic hypertension Health Maintenance Organizations (HMOs) National Health Insurance scheme (NHIS) cost of illness.

References (13)

  1. 1 Global status report on noncommunicable diseases 2010.
  2. 2 Factors Associated with Treatment Compliance in Hypertension in Southwest Nigeria [DOI]
  3. 3 Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa [DOI]
  4. 4 A meta analysis of prevalence rate of hypertension in Nigerian populations [DOI]
  5. 5 Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria [DOI]
  6. 6 A meta analysis of prevalence rate of hypertension in Nigerian populations [DOI]
  7. 7 Improving Poverty Alleviation Programmes in Nigeria through Small and Medium Scale Agricultural Development Projects
  8. 8 A review of the Nigerian health care funding system and how it compares to that of South Africa, Europe and America
  9. 9 The structure of risk adjustment for private plans in Medicare.
  10. 10 First-line medicines in the treatment of hypertension [DOI]
  11. 11 Variations in Medicare Health Maintenance Organizations [DOI]
  12. 12 Costs related to medical treatment for common cardiovascular risk factors.
  13. 13 Sample Size Tables [DOI]

Cited by 11

Effect of Reflex Therapy on Stress and Blood Pressure among Older Adults with Hypertension

Sahbanathul Missiriya, J. Suhail Hassan, Arul Anunncia · Journal of Pharmaceutical Research International · 2020

Health Insurance Uptake and Affordability of Care Among Patients with Hypertension in a Federal Teaching Hospital in Southwestern Nigeria

T. Ipinnimo, Demilade Ibirongbe, M. Omowaye · Journal of Health and Medical Sciences · 2021

Showing 9 of 11 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

56

Page views

0

PDF downloads

20

Outbound clicks

11

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.